Pushkal Garg Alnylam Pharmaceuticals, Inc. (ALNY) insider trading activity

ALNY Quotes by TradingView

Pushkal Garg is CMO & EVP Dev & Med Affairs of ALNYLAM PHARMACEUTICALS, INC.. Currently has a direct ownership of 11,989 shares of ALNY, which is worth approximately $3 Million. The most recent transaction as insider was on Feb 18, 2025, when has been sold 1,548 shares (Common Stock) at a price of $254.26 per share, resulting in proceeds of $393,594. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 12K
23.66% 3M change
63.52% 12M change
Total Value Held $3 Million

Pushkal Garg Transaction History

Date Transaction Value Shares Traded Shares Held Form
Feb 18 2025
SELL
Open market or private sale
$393,594 $254.26 p/Share
1,548 Reduced 11.44%
11,989 Common Stock
Feb 14 2025
SELL
Open market or private sale
$402,940 $258.13 p/Share
1,561 Reduced 10.34%
13,537 Common Stock
Feb 13 2025
BUY
Grant, award, or other acquisition
-
3,109 Added 17.08%
15,098 Common Stock
Jan 27 2025
SELL
Open market or private sale
$14,988,720 $285.0 p/Share
52,592 Reduced 81.44%
11,989 Common Stock
Jan 27 2025
BUY
Exercise of conversion of derivative security
$4,347,520 $88.95 p/Share
48,876 Added 43.08%
64,581 Common Stock
Dec 12 2024
SELL
Open market or private sale
$440,838 $251.62 p/Share
1,752 Reduced 10.04%
15,705 Common Stock
Nov 26 2024
SELL
Open market or private sale
$421,088 $250.35 p/Share
1,682 Reduced 8.79%
17,457 Common Stock
Nov 25 2024
BUY
Grant, award, or other acquisition
-
3,434 Added 15.21%
19,139 Common Stock
Oct 08 2024
BUY
Grant, award, or other acquisition
-
96 Added 0.61%
15,705 Common Stock
Jun 25 2024
SELL
Open market or private sale
$482,470 $229.42 p/Share
2,103 Reduced 11.87%
15,609 Common Stock
Jun 24 2024
BUY
Grant, award, or other acquisition
-
4,295 Added 19.52%
17,712 Common Stock
Mar 01 2024
BUY
Grant, award, or other acquisition
-
4,751 Added 26.15%
13,417 Common Stock
Feb 28 2024
SELL
Open market or private sale
$89,744 $156.35 p/Share
574 Reduced 6.21%
8,666 Common Stock
Feb 27 2024
BUY
Exercise of conversion of derivative security
-
1,908 Added 17.12%
9,240 Common Stock
Feb 16 2024
SELL
Open market or private sale
$193,924 $148.26 p/Share
1,308 Reduced 15.14%
7,332 Common Stock
Feb 15 2024
BUY
Grant, award, or other acquisition
-
4,295 Added 33.2%
8,640 Common Stock
Aug 07 2023
SELL
Open market or private sale
$768,710 $184.52 p/Share
4,166 Reduced 48.95%
4,345 Common Stock
Aug 04 2023
SELL
Open market or private sale
$647,033 $186.95 p/Share
3,461 Reduced 28.91%
8,511 Common Stock
Aug 03 2023
BUY
Grant, award, or other acquisition
-
7,627 Added 38.92%
11,972 Common Stock
Apr 28 2023
SELL
Open market or private sale
$487,440 $198.55 p/Share
2,455 Reduced 36.1%
4,345 Common Stock
Apr 27 2023
SELL
Open market or private sale
$358,531 $194.96 p/Share
1,839 Reduced 21.29%
6,800 Common Stock
Apr 26 2023
BUY
Grant, award, or other acquisition
-
4,294 Added 33.2%
8,639 Common Stock
Mar 03 2023
SELL
Open market or private sale
$3,614,400 $200.0 p/Share
18,072 Reduced 80.62%
4,345 Common Stock
Mar 03 2023
BUY
Exercise of conversion of derivative security
$482,250 $96.45 p/Share
5,000 Added 18.24%
22,417 Common Stock
Aug 04 2022
SELL
Payment of exercise price or tax liability
$1,036,985 $203.89 p/Share
5,086 Reduced 22.6%
17,417 Common Stock

Also insider at

SQZ
SQZ Biotechnologies Co Healthcare
Director
PG

Pushkal Garg

CMO & EVP Dev & Med Affairs
Cambridge, MA

Track Institutional and Insider Activities on ALNY

Follow ALNYLAM PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ALNY shares.

Notify only if

Insider Trading

Get notified when an Alnylam Pharmaceuticals, Inc. insider buys or sells ALNY shares.

Notify only if

News

Receive news related to ALNYLAM PHARMACEUTICALS, INC.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on ALNY